Get Blog Posts By Email
Category Archives: 2017
The Prostate Cancer Foundation recently published a 32-page guide containing diet recommendations for men living with prostate cancer. There is considerable discussion on plant-based foods, dietary fats, sugar, beverages and nutrients. See the following link for the guide.
For several weeks, I had been undergoing a cutting-edge, experimental cancer treatment. I firmly believed God had led me to this stage by a totally unexpected but logical pathway. My oncologist had also enthusiastically concurred with my choice. One of more »
Zero-the project to end prostate cancer is sponsoring a webcast on advanced prostate cancer. The webcast is scheduled for Tuesday, December 19th at 7-8 PM. For registration and information, see the following link.
I personally know of two Vietnam era veterans who were exposed to Agent Orange during their military service; both contracted prostate cancer. Hence it was of interest that I read the following linked article from the Prostate Cancer Foundation describing more »
HIGHLY RECOMMENDED: The Prostate Cancer Foundation (PCF) recently published (November 2017) an electronic patient guide which can be downloaded to your computer or obtained as a hard copy. Main topics include: 1) You and Prostate Cancer – General Information -Medical Basics; more »
Adding Xtandi® (enzalutamide) to hormone therapy reduces the risk of cancer spreading in patients with non-metastatic, hormone-resistant prostate cancer (CRPC), new Phase 3 trial data shows. Additional results were announced by Pfizer and Astellas Pharma, the drug developers. “Many prostate cancer patients who more »
Apalutamide (ARN-509), a Potential New Therapy for Non-Metastatic Hormone-Resistant Prostate Cancer.
Janssen-Biotech has submitted a new drug application to the Food and Drug Administration (FDA) for apalutamide (ARN-509) to treat non-metastatic hormone-resistant prostate cancer. Apalutamide is an oral androgen receptor inhibitor that blocks the action of testosterone in prostate cancer cells. (Whether more »
In December 2016, when I first embarked on my latest course of prostate cancer treatments, it seemed logical to me to treat the cancer first by stimulating my immune system; therefore, Provenge® (sipuleucel-T) was my first choice. That course of more »
For men with metastatic, hormone-resistant prostate cancer, treatment with Taxotere (docetaxel) and prednisone has been shown to improve survival. But few treatment strategies are available if this first-line therapy fails. Second-line therapy of anti-cancer agent Jevtana with the steroid medicine more »
DNA sequencing of a person’s tumor can be very important in determining treatment plans among other potential applications. The National Cancer Institute (NCI) today published an excellent review of methods used to obtain a person’s genetic information and how this more »